Columnist G Shellye Horowitz was nervous to visit a new doctor, but says she felt reassured by three comments the ...

Hemophilia A follows an X-linked recessive inheritance pattern, meaning the altered gene resides on the X chromosome. This genetic arrangement explains several characteristic patterns observed in ...

Still, medications to treat hemophilia on average cost more than $270,000 annually per patient, according to a 2015 Express Scripts report, and they can easily soar past $1 million annually.

Over 5 years of treatment in hemophilia B patients, gene therapy research shows sustained factor IX activity and safety.

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and adolescents living with hemophilia A or B with inhibitors in a late-stage ...

The Food and Drug Administration (FDA) has approved Alhemo ® (concizumab-mtci) injection for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric ...

Pfizer’s hemophilia A gene therapy reduced annualized bleeding rates in a Phase 3 clinical trial, setting the stage for discussions with regulators. However, the market for such one-time ...

U.S. drugmaker Pfizer Inc said on Thursday its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study.